SPRUCE BIOSCIENCES, INC.

SPRBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1683553

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenues	$4.9M	$10.1M	$0.00	—	—
Research and Development Expense	$46.4M	$49.4M	$35.2M	$30.7M	$23.9M
Operating Expenses	$61.1M	$62.1M	$47.3M	$42.1M	$29.4M
Operating Income (Loss)	-$56.2M	-$52.0M	-$47.3M	-$42.1M	-$29.4M
Interest Expense	$307.0K	$483.0K	$420.0K	$345.0K	$323.0K
Other Nonoperating Income (Expense)	—	—	—	—	$200.0K
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$45.2M	$103.9M	$85.6M	$126.5M	$162.9M
Assets, Current	$44.2M	$102.2M	$83.6M	$91.9M	$160.4M
Cash and Cash Equivalents, at Carrying Value	$38.8M	$96.3M	$24.5M	$42.7M	$157.2M
Liabilities	$16.4M	$27.4M	$17.2M	$15.1M	$13.5M
Liabilities, Current	$15.2M	$24.5M	$12.4M	$8.9M	$9.8M
Long-term Debt	—	$1.8M	$3.7M	$5.6M	$4.5M
Accounts Payable, Current	$1.3M	$3.3M	$1.4M	$2.8M	$3.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$56.0M	-$33.3M	-$41.7M	-$35.9M	-$27.5M
Net Cash Provided by (Used in) Investing Activities	—	$55.8M	$23.7M	-$79.2M	-$74.0K
Net Cash Provided by (Used in) Financing Activities	-$1.6M	$49.1M	-$241.0K	$643.0K	$181.0M
Payments to Acquire Property, Plant, and Equipment	—	$7.0K	$8.0K	$93.0K	$74.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)